Summary of Significant Accounting Policies and Select Balance Sheet Information (Tables)

12 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Amortized Cost, Unrealized Holding Gains (Losses) and Fair Value of Available for Sale Securities

The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows:

	September 30, 2020
(In thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Commercial paper and corporate bonds	$	30,313	$	19	$	(19	)	$	30,313
Total	$	30,313	$	19	$	(19	)	$	30,313

	September 30, 2019
(In thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Commercial paper and corporate bonds	$	24,918	$	13	$	—	$	24,931
Total	$	24,918	$	13	$	—	$	24,931

Components of Inventories

Inventories consisted of the following components:

Schedule of Property, Plant and Equipment

Property and equipment consisted of the following components:

	Useful Life	September 30,
(Dollars in thousands)	(Years)	2020			2019
Land	N/A	$	4,419		$	4,415
Laboratory fixtures and equipment	3 to 12		28,600			25,467
Buildings and improvements	3 to 20		25,638			24,513
Leasehold improvements	3 to 10		4,836			4,836
Office furniture and equipment	3 to 10		7,334			6,476
Construction-in-progress			2,238			2,030
Less: Accumulated depreciation			(42,962	)		(37,989	)
Property and equipment, net		$	30,103		$	29,748

Summary of Other Assets

Other assets consisted of the following:

	September 30,
(In thousands)	2020		2019
ViaCyte, Inc.	$	—	$	479
Operating lease right-of-use assets		2,508		—
Other noncurrent assets		1,761		1,645
Other assets, net	$	4,269	$	2,124

Schedule of Intangible Assets

Intangible assets consisted of the following:

	September 30, 2020
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	18,213	$	(12,451	)	$	5,762
Developed technology		11.5		9,685		(4,200	)		5,485
Non-compete		5.0		230		(230	)		—
Patents and other		14.7		3,321		(1,865	)		1,456
Total definite-lived intangible assets				31,449		(18,746	)		12,703
Unamortized intangible assets:
Trademarks and trade names				580		—			580
Total intangible assets			$	32,029	$	(18,746	)	$	13,283

	September 30, 2019
(Dollars in thousands)	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists and relationships		8.9	$	17,374	$	(10,661	)	$	6,713
Developed technology		11.5		9,490		(3,196	)		6,294
Non-compete		5.0		230		(196	)		34
Patents and other		16.5		2,321		(1,716	)		605
Total definite-lived intangible assets				29,415		(15,769	)		13,646
Unamortized intangible assets:
Trademarks and trade names				580		—			580
Total intangible assets			$	29,995	$	(15,769	)	$	14,226

Estimated Amortization Expense

Based on the intangible assets in service as of September 30, 2020, estimated amortization expense for each of the next five fiscal years is as follows:

(In thousands)
2021	$	2,488
2022		2,448
2023		1,843
2024		1,750
2025		1,712

Schedule of Carrying Amount of Goodwill By Reportable Segment

Changes in the carrying amount of goodwill by reportable segment were as follows:

(In thousands)	In Vitro Diagnostics		Medical Device			Total
Balance as of September 30, 2018	$	8,010	$	19,022		$	27,032
Foreign currency translation adjustment		—		(861	)		(861	)
Balance as of September 30, 2019		8,010		18,161			26,171
Foreign currency translation adjustment		—		1,014			1,014
Balance as of September 30, 2020	$	8,010	$	19,175		$	27,185

Schedule of Accrued Other Liabilities

Accrued other liabilities consisted of the following:

	September 30,
(In thousands)	2020		2019
Accrued professional fees	$	239	$	434
Accrued clinical study expense		2,206		2,163
Accrued purchases		647		679
Acquisition of in-process research and development and     intangible assets		1,148		989
Due to customers		321		19
Construction-in-progress		272		—
Operating lease liability, current portion		436		—
Deferred rent, current portion		—		130
Other		278		376
Total accrued other liabilities	$	5,547	$	4,790

Denominator for Computation of Basic and Diluted Net Income (Loss) Per Share

The following table sets forth the denominator for the computation of basic and diluted net income (loss) per share:

	Fiscal Year
(In thousands)	2020		2019		2018
Net income (loss) available to common shareholders	$	1,123	$	7,592	$	(4,457	)
Basic weighted average shares outstanding		13,552		13,389		13,157
Dilutive effect of outstanding stock options, non-vested     restricted stock, and non-vested restricted stock units		260		390		—
Diluted weighted average shares outstanding		13,812		13,779		13,157

Balance Sheet Classification and Amounts of Right-of-Use Assets and Lease Liabilities

Operating lease right-of-use assets and lease liabilities were as follows:

(In thousands)	September 30, 2020
Right-of-use assets:
Other assets	$	2,508
Operating lease liabilities:
Other accrued liabilities	$	436
Other long-term liabilities		3,340
Total operating lease liabilities	$	3,776

Schedule of Operating Lease Maturities

As of September 30, 2020, operating lease maturities for each of the next five fiscal years were as follows:

(In thousands)
2021	$	586
2022		612
2023		625
2024		638
2025		651
Thereafter		1,521
Total expected operating lease payments		4,633
Less: Imputed interest		(857	)
Total operating lease liabilities	$	3,776